title: Fragile X syndrome therapeutics S(C)TEP through the developmental window.
abstract: Treatment for fragile X syndrome and related autism spectrum disorders has long been thought to be effective only during a narrow window early in development. In this issue of Neuron, Michalon et al. (2012) dispel this myth.
authors.affiliation: Center for Neural Science, New York University, New York, NY 10003, USA.
authors.forename: Aditi
authors.initials: A
authors.lastname: Bhattacharya
authors.forename: Eric
authors.initials: E
authors.lastname: Klann
mesh_terms: D000818:Animals; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005600:Fragile X Syndrome / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D011725:Pyridines / Q000627:therapeutic use*; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects*
chemical_list: C569289:2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine; D018691:Excitatory Amino Acid Antagonists; D007093:Imidazoles; D011725:Pyridines; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate